Viloxazine (brand name Qelbree) is not a controlled substance. The DEA assigns it no schedule, which means it carries no special prescribing restrictions related to abuse potential. This makes it fundamentally different from stimulant ADHD medications like amphetamine and methylphenidate, which are Schedule II controlled substances with strict limits on refills and prescribing.
Why Viloxazine Has No DEA Schedule
The FDA’s Controlled Substance Staff reviewed viloxazine’s abuse potential before its 2021 approval and determined it did not warrant scheduling. In animal studies, viloxazine did not produce behaviors associated with abuse potential. Animals given the drug chronically showed no signs of withdrawal when it was stopped, suggesting no physical dependence develops.
No formal human abuse potential study was conducted, but data from clinical trials filled in the picture. Across Phase 2 and Phase 3 studies, abuse-related side effects occurred at very low rates in people taking viloxazine (between 0.05% and 1.48% of participants). The few overdose cases that did occur were medication errors, like accidentally taking two capsules instead of one, and none were linked to drug-seeking behavior. When viloxazine was given alongside common stimulant ADHD medications, there was no increase in abuse-related effects. There was also no indication of tolerance building up over time.
At supratherapeutic doses (higher than what would be prescribed), a small number of healthy volunteers in early-phase studies reported euphoria or visual hallucinations. But these were isolated events, not a pattern that pointed toward meaningful abuse liability.
How It Differs From Stimulant ADHD Medications
Viloxazine works by blocking the reabsorption of norepinephrine in the brain, which helps improve attention and impulse control without directly increasing dopamine levels the way stimulants do. This mechanism is a key reason it lacks abuse potential. Stimulants like amphetamine rapidly boost dopamine in reward pathways, which creates the “high” that drives misuse. Viloxazine simply doesn’t do that.
In practical terms, this non-controlled status affects how you get your prescription. Stimulant medications typically require a new written prescription each month, with no automatic refills and limits on early fills. Viloxazine can be prescribed with refills like most standard medications, which makes the logistics of staying on treatment considerably easier.
What Viloxazine Is Approved For
The FDA approved viloxazine extended-release capsules in April 2021 for treating ADHD in children and adolescents ages 6 to 17. It has since received approval for adults as well. The drug is not entirely new, though. Viloxazine was marketed in Europe as an antidepressant from the 1970s until 2008, when it was voluntarily withdrawn for commercial reasons (not safety concerns). In the U.S., it had never been approved or sold before Qelbree launched.
Common Side Effects
While viloxazine doesn’t carry abuse risks, it does have a meaningful side effect profile. The most common reactions differ somewhat between children and adults.
In pediatric trials involving over 800 patients, the most frequent side effects compared to placebo were sleepiness (16% vs. 4%), headache (11% vs. 7%), decreased appetite (7% vs. 0.4%), and fatigue (6% vs. 2%). Nausea, vomiting, and insomnia each affected 4-5% of children taking the medication.
Adults experienced a somewhat different pattern. Insomnia was the standout issue, affecting 23% of adults on viloxazine versus 7% on placebo. Headache (17%), nausea (12%), fatigue (12%), decreased appetite (10%), and dry mouth (10%) were also notably more common than with placebo.
Heart Rate and Blood Pressure Effects
Viloxazine can increase heart rate and blood pressure, which is worth knowing even though it’s unrelated to its controlled substance status. In trials of children ages 6 to 11, between 22% and 31% experienced a heart rate increase of 20 or more beats per minute at some point during treatment, depending on the dose, compared to 9-15% on placebo. Similar patterns appeared in adolescents and adults. About 29% of adults on viloxazine had a heart rate jump of 20 or more beats per minute, compared to 13% on placebo.
Blood pressure changes were more modest but still present. Roughly 25% of adolescents on the higher dose and 13% of adults showed clinically meaningful increases in diastolic blood pressure during their trials.
The Black Box Warning
Viloxazine carries an FDA black box warning for suicidal thoughts and behaviors, the most serious type of safety warning a medication can have. In pediatric trials, 0.9% of the roughly 1,000 children and adolescents taking viloxazine reported suicidal thoughts or behavior, compared to 0.4% on placebo. Among adults, 1.6% of those on viloxazine reported suicidal ideation versus none on placebo. These rates are low in absolute terms, but the difference from placebo was consistent enough to warrant the warning and close monitoring during treatment.